Drug Profile
Research programme: intranasal urinary tract infections vaccine
Latest Information Update: 09 May 2018
Price :
$50
*
At a glance
- Originator NanoBio Corporation; University of Michigan
- Developer BlueWillow Biologics
- Class Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Urinary tract infections
Most Recent Events
- 07 May 2018 NanoBio Corporation is now called BlueWillow Biologics
- 16 Jul 2016 No recent reports of development identified for research development in Urinary-tract-infections in USA (Intranasal)
- 21 Apr 2011 Early research in Urinary tract infections in USA (Intranasal)